JMP maintains NeoPharm at strong buy

NeoPharm, Inc. was maintained by JMP Securities analyst Charles C. Duncan at a strong buy rating with a $19 price target after lower-than-expected September enrollment of a phase 3 Precise trial in glioblastoma; shares tumbled 30% in October. If data on the company's NeoLipid program on LerafAON-ETU at an upcoming medical conference is positive, it could enhance investor conviction in NeoPharm's pipeline and in the stock, JMP said. Shares of the Lake Forest, Ill.-based biopharmaceutical company were up $0.12, or 1.21%, at $10.04 on volume of 153,318 shares versus the three-month running average of 310,024 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.